Summary of HR 3866: Maternal and Infant Syphilis Prevention Act

Purpose and Intent

The Maternal and Infant Syphilis Prevention Act (HR 3866) aims to address the rising rates of syphilis infections among pregnant individuals and infants in the United States. The bill seeks to enhance prevention, screening, and treatment efforts to protect maternal and infant health, thereby reducing the incidence of congenital syphilis and related complications.

Key Provisions

While the specific text of the bill is not provided, the following key provisions are typically included in legislation of this nature:

• Increased Funding: The bill may propose increased federal funding for programs aimed at preventing syphilis infections in pregnant individuals and infants.

• Enhanced Screening Protocols: It is likely to establish or recommend standardized screening protocols for syphilis during prenatal care visits to ensure early detection and treatment.

• Public Awareness Campaigns: The bill may include provisions for public health campaigns to educate communities about the risks of syphilis and the importance of testing and treatment.

• Collaboration with Healthcare Providers: The legislation may encourage partnerships between public health agencies and healthcare providers to improve access to testing and treatment services.

• Data Collection and Reporting: The bill could mandate improved data collection on syphilis rates among pregnant individuals and infants to better inform public health strategies.

Who Would Be Affected

• Pregnant Individuals: The primary beneficiaries of this legislation would be pregnant individuals, who would receive better access to screening and treatment for syphilis.

• Infants: Newborns would benefit from reduced rates of congenital syphilis, leading to better health outcomes.

• Healthcare Providers: Medical professionals would be impacted through the implementation of new screening protocols and potential training initiatives.

• Public Health Agencies: These agencies would see an increase in funding and responsibilities related to syphilis prevention and education efforts.

Legislative Process and Timeline

• Introduced: The bill was introduced in the House on June 10, 2025.

• Committee Referral: On the same day, it was referred to the Committee on Energy and Commerce and the Committee on Natural Resources for consideration. The timeline for further action will be determined by the Speaker of the House.

• Companion Bill: The bill has a companion in the Senate, S 2004, which may facilitate parallel discussions and potential passage in both chambers.

Conclusion

The Maternal and Infant Syphilis Prevention Act (HR 3866) represents a proactive approach to combatting the public health issue of syphilis among pregnant individuals and infants. By enhancing prevention measures and ensuring better access to healthcare, this legislation aims to improve health outcomes and reduce the incidence of congenital syphilis in the United States.